{"version":"1.0","provider_name":"FYB Financial Yearbook","provider_url":"https:\/\/www.fyb.de\/en\/","author_name":"Tatjana Anderer","author_url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/","title":"Bayer to divest prescription dermatology business - FYB Financial Yearbook","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"pfTXhFqVXq\"><a href=\"https:\/\/www.fyb.de\/en\/bayer-to-divest-prescription-dermatology-business\/\">Bayer to divest prescription dermatology business<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.fyb.de\/en\/bayer-to-divest-prescription-dermatology-business\/embed\/#?secret=pfTXhFqVXq\" width=\"600\" height=\"338\" title=\"&#8220;Bayer to divest prescription dermatology business&#8221; &#8212; FYB Financial Yearbook\" data-secret=\"pfTXhFqVXq\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/08\/a-wentrup-e1533122508503.jpg","thumbnail_width":543,"thumbnail_height":373,"description":"Leverkusen\/ D\u00fcssel\u00addorf \u2014 Bayer has signed an agree\u00adment with LEO Pharma for the sale of Bayer\u2019s global prescrip\u00adtion derma\u00adto\u00adlogy busi\u00adness. The port\u00adfo\u00adlio to be acqui\u00adred includes bran\u00added prescrip\u00adtion products for the topi\u00adcal treat\u00adment of acne, fungal skin infec\u00adtions and rosacea, as well as a range of topi\u00adcal stero\u00adids with annual sales of over EUR 280 [&hellip;]"}